Biotech investor raises billion in new fund
The firm takes a different approach to investing compared to other venture-capital funds: Arch focuses on commercializing technology developed at a...
The firm takes a different approach to investing compared to other venture-capital funds: Arch focuses on commercializing technology developed at academic institutions and, most of the time, it says it co-founds companies with scientists. Arch's checks range from $50,000 to hundreds of millions of dollars, depending on the type of company, says spokeswoman Danielle Cantey. With the new fund, Arch plans to invest in companies addressing infectious disease, mental health, immunology, oncology, neurology and clinical trials, among other things.